<DOC>
	<DOCNO>NCT00688818</DOCNO>
	<brief_summary>This multi-centred study conduct three centre . The design randomize , placebo-controlled , parallel-group one . This investigation evaluate efficacy add-on Quetiapine XR ( extended release ) treatment patient meet diagnostic criterion depressive disorder one comorbid anxiety disorder .</brief_summary>
	<brief_title>Quetiapine Co-Morbid Depressive Anxiety Disorders</brief_title>
	<detailed_description>The primary objective examine beneficial effect quetiapine augmentation first-line antidepressant refractory depression co-morbid anxiety , compare placebo . It hypothesize significant improvement depression anxiety symptom see evidence reduction Hamilton Depression Rating Scale ( HAMD-17 ) Hamilton Anxiety Scale ( HAMA ) score 12 week treatment period receive Quetiapine XR augmentation compare receive placebo.2.2 Secondary objective : 1 ) To establish tolerability safety Quetiapine XR versus Placebo patient co-morbid depressive anxiety disorder ; 2 ) To assess compare efficacy Quetiapine XR versus Placebo improving quality life patient co-morbid depressive anxiety disorder . ; 3 ) To assess compare efficacy Quetiapine XR versus Placebo clinical measure symptom associate co-morbid depressive anxiety disorder .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Anxiety Disorders</mesh_term>
	<mesh_term>Depressive Disorder</mesh_term>
	<mesh_term>Depression</mesh_term>
	<mesh_term>Stress Disorders , Traumatic</mesh_term>
	<mesh_term>Depressive Disorder , Major</mesh_term>
	<mesh_term>Stress Disorders , Post-Traumatic</mesh_term>
	<mesh_term>Panic Disorder</mesh_term>
	<mesh_term>Phobic Disorders</mesh_term>
	<mesh_term>Dysthymic Disorder</mesh_term>
	<mesh_term>Quetiapine Fumarate</mesh_term>
	<criteria>Provision write informed consent Male female patient must 18 65 year age . Women childbearing potential must negative pregnancy test must , investigator 's opinion , practice clinically accept , reliable method contraception study . A diagnosis Major Depressive Disorder Dysthymic Disorder define DSMIV criterion fail respond least one first line treatment . The patient must receive antidepressant treatment ( SSRIs , SNRIs mirtazapine ) . A comorbid diagnosis one following : Generalized Anxiety Disorder , Social Anxiety Disorder , Panic Disorder , Post Traumatic Stress Disorder , ObsessiveCompulsive Disorder , define DSMIV criterion A minimum score â‰¥17 Baseline 17item HAMD . Able understand comply requirement study The presence history Psychotic Disorders , Bipolar Disorders , Mood Disorders Psychotic Features Patients , investigator 's judgment , would require treatment additional psychotherapeutic drug , electroconvulsive therapy ( ECT ) , intensive psychotherapy course study . ECT within precede 6 month screen inclusion . Regular , formal psychotherapy ( exclude supportive therapy ) start within last 3 month inclusion . Patients , opinion investigator , pose imminent risk suicide danger self others Known intolerance lack response quetiapine fumarate . Use follow cytochrome P450 3A4 inhibitor 14 day precede enrolment Use follow significant cytochrome P450 inducer 14 day precede enrolment Patients currently receive : monoamine oxidase inhibitor , tricyclic antidepressant , oral neuroleptic , type 1C antiarrhythmic within two week screen ; herbal psychoactive treatment ( St. John 's Wort , Kava Kava , Gingko Biloba ) within two week screen . Patients take SSRIs SNRIs less two week less therapeutic dose prior enrolment . Patients require concurrent psychotropic medication allow medication specify protocol . Administration depot antipsychotic injection within one dose interval ( depot ) randomisation . Patients meet DSMIV criterion abuse dependence drug , include alcohol within 3 month prior screen . Medical condition would affect absorption , distribution , metabolism , excretion study treatment Unstable inadequately treat medical illness ( e.g . congestive heart failure , angina pectoris , hypertension ) judge investigator Patients clinically significant abnormality hematology , clinical chemistry , urinalysis ECG screen visit . Involvement plan conduct study Previous enrolment randomisation treatment present study . Participation another drug trial within 4 week prior enrolment study long accordance local requirement A patient Diabetes Mellitus ( DM ) fulfil one follow criterion : ) Unstable DM ( HbA1c ) &gt; 8.5 % , b ) hospital admission DM DM relate illness past 12 week , c ) physician care DM , ) physician responsible patient 's DM care approve patient 's participation study , indicate DM control e ) change dose oral hypoglycaemic drug ( ) and/or diet 4 week prior randomisation . For thiazolidinediones ( glitazones ) period le 8 week , g ) take insulin whose daily dose one occasion past 4 week 10 % mean dose precede 4 week ( Note : If diabetic patient meet one criterion , patient exclude even treat physician believe patient stable participate study ) An absolute neutrophil count ( ANC ) &lt; = 1.5 x 10^9 per</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>August 2014</verification_date>
	<keyword>Co-morbid depressive anxiety disorder</keyword>
	<keyword>Quetiapine</keyword>
	<keyword>Randomized</keyword>
	<keyword>Placebo-controlled</keyword>
	<keyword>Double-blind</keyword>
	<keyword>Major depressive disorder</keyword>
	<keyword>Dysthymic disorder</keyword>
	<keyword>Anxiety disorder</keyword>
	<keyword>Generalized anxiety disorder</keyword>
	<keyword>Social anxiety disorder</keyword>
	<keyword>Panic disorder</keyword>
	<keyword>Post-traumatic stress disorder</keyword>
</DOC>